This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds
by Zacks Equity Research
Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.
Buy These 5 Low Leverage Stocks to Keep Your Portfolio Safe
by Aparajita Dutta
To safeguard one's portfolio from massive losses, the real challenge for an investor is to determine whether an organization's debt level is sustainable.
SYNH vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SYNH vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.
Omnicell (OMCL) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 5.56% and -1.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell Advances on Global Footing Despite Severe Rivalry
by Zacks Equity Research
Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.
Bright Near-Term Outlook for Medical Info Systems Industry
by Sreyoshi Mukherjee
Growth prospects look bright for the Zacks Medical Info Systems industry, thanks to rising need for curtailing medical expenses and AI.
Omnicell's Autonomous Pharmacy to Boost Medication Management
by Zacks Equity Research
Omnicell (OMCL) aims to combine technology and innovation to enable pharmacists to expand their outreach to patients and improve services.
Omnicell (OMCL) Up 0.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on Omnicell's (OMCL) prospects.
Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) aims at product innovation through R&D.
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 4.69% and 1.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Omnicell (OMCL) Catches Eye: Stock Jumps 8.2%
by Zacks Equity Research
Omnicell (OMCL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Here's Why You Should Invest in Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Why Is Omnicell (OMCL) Up 4.8% Since Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Omnicell (OMCL) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NXGN vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.
Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell's Global Expansion on Track, Stiff Competition Ails
by Zacks Equity Research
Although Omnicell (OMCL) is steadily expanding in the Middle East and South African belts, it sees a greater uptake of technologies across other regions of the world.